Halozyme Therapeutics, Inc. (FRA:RV7)
Germany · Delayed Price · Currency is EUR 60.96
-1.18 (-1.90%)
At close: Feb 20, 2026
Halozyme Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 316.89 | 444.09 | 281.59 | 202.13 | 402.71 |
Depreciation & Amortization | 88.05 | 81.31 | 84.86 | 49.64 | 3 |
Other Amortization | 7.51 | 7.35 | 7.3 | 7.84 | 3.64 |
Loss (Gain) From Sale of Assets | 2.62 | 1.53 | 0.61 | 0.13 | - |
Asset Writedown & Restructuring Costs | 333.59 | - | - | - | - |
Loss (Gain) From Sale of Investments | -3.47 | -10.93 | -6.32 | 2.83 | 2.26 |
Stock-Based Compensation | 51.57 | 43.39 | 36.62 | 24.4 | 20.82 |
Other Operating Activities | 7.06 | 1.6 | 22.58 | 39.09 | -136.72 |
Change in Accounts Receivable | -128.06 | -74.25 | -3.34 | -83.94 | 6.76 |
Change in Inventory | 2.55 | -67.38 | -26.88 | -17.48 | 7.37 |
Change in Accounts Payable | 6.21 | 46.99 | -12.55 | 24.54 | 1.17 |
Change in Other Net Operating Assets | -32.96 | 5.36 | 4.1 | -9.06 | -11.56 |
Operating Cash Flow | 651.56 | 479.06 | 388.57 | 240.11 | 299.44 |
Operating Cash Flow Growth | 36.01% | 23.29% | 61.83% | -19.81% | 439.98% |
Capital Expenditures | -6.97 | -10.7 | -15.29 | -4.81 | -1.46 |
Sale of Property, Plant & Equipment | - | - | - | 26.01 | - |
Cash Acquisitions | -725.97 | - | - | -999.12 | - |
Sale (Purchase) of Intangibles | -287.77 | - | - | - | - |
Investment in Securities | 474.89 | -252.03 | -81.62 | 490.92 | -404.83 |
Investing Cash Flow | -545.81 | -262.72 | -96.91 | -487.01 | -406.29 |
Short-Term Debt Issued | - | - | - | 370 | - |
Long-Term Debt Issued | 1,470 | - | - | 702 | 784.88 |
Total Debt Issued | 1,470 | - | - | 1,072 | 784.88 |
Short-Term Debt Repaid | - | - | - | -370 | - |
Long-Term Debt Repaid | -845.43 | - | -13.48 | -77.45 | -369.06 |
Total Debt Repaid | -845.43 | - | -13.48 | -447.45 | -369.06 |
Net Debt Issued (Repaid) | 624.57 | - | -13.48 | 624.55 | 415.81 |
Issuance of Common Stock | 21.83 | 31.14 | 7.88 | 14.05 | 12.54 |
Repurchase of Common Stock | -342.37 | -250 | -402.38 | -200 | -350.06 |
Other Financing Activities | -389.21 | - | - | -76.22 | -0.42 |
Financing Cash Flow | -85.17 | -218.86 | -407.99 | 362.37 | 77.87 |
Net Cash Flow | 20.57 | -2.52 | -116.33 | 115.48 | -28.98 |
Free Cash Flow | 644.59 | 468.37 | 373.28 | 235.3 | 297.98 |
Free Cash Flow Growth | 37.62% | 25.47% | 58.64% | -21.04% | 462.76% |
Free Cash Flow Margin | 46.15% | 46.13% | 45.01% | 35.64% | 67.22% |
Free Cash Flow Per Share | 5.20 | 3.62 | 2.78 | 1.67 | 2.03 |
Cash Interest Paid | 11.43 | 10.57 | 11.41 | 6.11 | 3.3 |
Cash Income Tax Paid | 134.64 | 80.62 | 31.76 | 16.22 | -0.38 |
Levered Free Cash Flow | 184.83 | 402.48 | 275.68 | 146.42 | 197.82 |
Unlevered Free Cash Flow | 188.65 | 406.44 | 280.1 | 149.17 | 198.88 |
Change in Working Capital | -152.26 | -89.28 | -38.67 | -85.95 | 3.74 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.